How Does iTind Work?
Mechanism of Action
The iTind
iTind is a temporarily implanted nitinol device which delivers rapid relief from BPH symptoms through a minimally invasive treatment.
The iTind is inserted in a simple and straightforward procedure. The device is placed into the prostate where it expands and exerts localized ischemic pressure on the tissue. This pressure aims to reshape the tissue of the prostatic urethra and the bladder neck, creating three longitudinal channels through which urine can flow.
Patients are able to return home during the 5-7 day treatment. After the implantation period of 5-7 days, the device is completely removed.
How Does iTind Work?
The iTind is placed in the prostatic urethra in a narrow, folded configuration under vision.
During the 5-7 day treatment, the device expands and exerts continuous pressure at the 5, 7 and 12 o’clock positions to remodel the prostatic urethra and the bladder neck.
After 5-7 days the device is completely removed, aiming to leave a wider opening through which urine can flow, and to relieve the symptoms of BPH.
Clinical Evidence 1
Clinical data demonstrate that the first generation TIND boasts a durability of three years, and powerful efficacy at 36 months is also demonstrated by the second-generation and commercially available iTind.
References
- 1.Company sponsored trials under the responsibility of Medi-Tate.
- 2.3-Year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction
- 3.Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up.
- 4.Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study.
- 5.3-Year results following treatment with the second generation of the temporary implantable nitinoldevice in men with LUTS secondary to benign prostatic obstruction
- 6.Urinary and sexual function after treatment with temporary implantable nitinol device (iTind) in men with LUTS: 6-month interim results of the MT-06-study.